Kimbi Gerald C, Kew Michael C, Yu Mimi C, Arakawa Kazuko, Hodkinson John
MRC/University Molecular Hepatology Research Unit, Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa.
J Gastroenterol Hepatol. 2005 Aug;20(8):1185-90. doi: 10.1111/j.1440-1746.2005.03951.x.
A specific mutation at codon 249 of the p53 tumor suppressor gene (guanine to thymine; arginine to serine [249(serine)p53]) is present in the cell-free plasma of 30-47% of patients with hepatocellular carcinoma (HCC) in regions with uniformly high levels of dietary exposure to the fungal toxin, aflatoxin B(1). No information is available from other regions. We therefore examined cell-free serum from HCC patients in southern Africa, where aflatoxin B(1) exposure ranges from very high to low levels.
DNA extracted from the serum of 158 black African patients with HCC was amplified by the polymerase chain reaction assay using primers specific for exon 7 of the p53 gene, and submitted to endonuclease cleavage with HaeIII to identify the 249(serine)p53 mutation. The presence of the mutation was confirmed by nucleotide sequencing.
The specific mutation was detected in 18% of the patients, giving an odds ratio for HCC in those with the mutation of 13.3 (95% confidence limits 1.8; 100.2). Surprisingly, the mutation was present equally often in rural and urban patients, despite presumed levels of aflatoxin B(1) exposure in the latter being much lower. No correlation was found with the presence of hepatitis B virus infection or the age, sex or tribe of the patients.
The 249(serine)p53 mutation is found less often in the serum of patients with HCC in a region with variable levels of exposure to aflatoxin B(1) than in those with uniformly high levels of exposure, but the mutation does occur in black Africans with presumed lower levels of exposure to the fungal toxin.
在膳食中黄曲霉毒素B1暴露水平普遍较高的地区,30% - 47%的肝细胞癌(HCC)患者的无细胞血浆中存在p53肿瘤抑制基因第249密码子的特定突变(鸟嘌呤突变为胸腺嘧啶;精氨酸突变为丝氨酸[249(丝氨酸)p53])。其他地区尚无相关信息。因此,我们检测了非洲南部HCC患者的无细胞血清,该地区黄曲霉毒素B1暴露水平从非常高到低不等。
采用针对p53基因第7外显子的引物,通过聚合酶链反应分析从158例非洲黑人HCC患者血清中提取的DNA,并使用HaeIII进行内切酶切割以鉴定249(丝氨酸)p53突变。通过核苷酸测序确认突变的存在。
18%的患者检测到该特定突变,突变患者患HCC的优势比为13.3(95%置信区间1.8;100.2)。令人惊讶的是,尽管城市患者的黄曲霉毒素B1暴露水平可能低得多,但农村和城市患者中该突变的出现频率相同。未发现与乙型肝炎病毒感染的存在或患者的年龄、性别或部落相关。
与黄曲霉毒素B1暴露水平普遍较高的地区相比,在黄曲霉毒素B1暴露水平不同的地区,HCC患者血清中249(丝氨酸)p53突变的发生率较低,但在推测黄曲霉毒素暴露水平较低的非洲黑人中确实存在该突变。